CD63 and non-small cell lung carcinoma: Many somatic mutations of EGFR, such as L858R (M1), L858R/T790M (M2), L858R/T790M/C797S (M3), Del E746-A750 (D1), Del E746-A750/T790M (D2) and Del E746-A750/T790M/C797S (D3), have been proven to be active without ligands in non-small cell lung cancer (NSCLC).28,29,53,54 These active EGFR mutants, but not WT EGFR (EGFRWT) resulted in tyrosine phosphorylation of both RAB31WT and RAB31Q65L (Supplementary information, Fig. S7d), and also drove RAB31WT and themselves entry into CD63-positive MVEs to form ILVs under serum starvation (Fig. 5d–g; Supplementary information, Fig. S7e, f).